MovDisordV3, PascalFrancis, Curation, bibRecord, 002969

Health-Related Quality-of-Life Scales in Parkinson's Disease: Critique and Recommendations

Identifieur interne : 002969 ( PascalFrancis/Curation ); précédent : 002968; suivant : 002970

Health-Related Quality-of-Life Scales in Parkinson's Disease: Critique and Recommendations

Auteurs : Pablo Martinez-Martin [Espagne] ; Martine Jeukens-Visser [Pays-Bas] ; Kelly E. Lyons [États-Unis] ; C. Rodriguez-Blazquez [Espagne] ; Caroline Selai [Royaume-Uni] ; Andrew Siderowf [États-Unis] ; Mickie Welsh [États-Unis] ; Werner Poewe [Autriche] ; Oliver Rascol [France] ; Cristina Sampaio [Portugal] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis] ; Anette Schrag [Royaume-Uni]

Source :

Movement disorders [ 0885-3185 ] ; 2011.

RBID : Pascal:12-0026974

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Qualité de vie, Recommandation, Homme, Pronostic.
Wicri :
- topic : Recommandation, Homme.

English descriptors

KwdEn :
- Human, Nervous system diseases, Parkinson disease, Prognosis, Quality of life, Recommendation.

Abstract

Health-related quality of life is an important patient-reported outcome used in intervention trials and for monitoring the consequences of health status on physical, mental, and social domains. Parkinson's disease is a complex disorder that strongly affects patients' quality of life. Several health-related quality of life tools have been used in Parkinson's disease. A Movement Disorder Society Task Force was commissioned to rate the psychometric quality of available health-related quality of life scales as applied to Parkinson's disease. Following the methodology adopted by previous work of the Movement Disorder Society Task Force, a review of generic and specific health-related quality of life scales applied in studies on Parkinson's disease was completed. Considering the scales from 3 perspectives-use in Parkinson's disease, use by multiple research groups, and clinimetric properties-a final classification as "recommended," "suggested," or "listed" was applied to each reviewed instrument. Four generic scales (EuroQoL, Nottingham Health Profile, 36-Item Short-Form Health Survey, and Sickness Impact Profile) and 5 specific scales (39-Item Parkinson's Disease Questionnaire, Parkinson's Disease Questionnaire Short Form, Parkinson's Disease Quality of Life Questionnaire, Parkinson's Impact Scale, and Scales for Outcomes in Parkinson's Disease-Psychosocial) reached the level of "recommended." The 39-item Parkinson's Disease Questionnaire is the most thoroughly tested and applied questionnaire. Three other generic measures (Quality of Life Questionnaire 15D, Schedule for the Evaluation of Individual Quality of Life-Direct Weighting, and World Health Organization Quality of Life Assessment Short Version) and the specific Parkinson's Disease Quality of Life Scale are "suggested." With a little additional effort in completing the stipulated requirements, they could reach the "recommended" level. At present there is a wide variety of health-related quality of life measures for application in the Parkinson's disease setting, and the task force does not recommend the development of a new scale. Selection of the most appropriate instrument for a particular objective requires consideration of the characteristics of each scale and the goals of the assessment.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 26`
A06				`@2 13`
A08	`01`	`1`	`ENG`	`@1 Health-Related Quality-of-Life Scales in Parkinson's Disease: Critique and Recommendations`
A11	`01`	`1`		`@1 MARTINEZ-MARTIN (Pablo)`
A11	`02`	`1`		`@1 JEUKENS-VISSER (Martine)`
A11	`03`	`1`		`@1 LYONS (Kelly E.)`
A11	`04`	`1`		`@1 RODRIGUEZ-BLAZQUEZ (C.)`
A11	`05`	`1`		`@1 SELAI (Caroline)`
A11	`06`	`1`		`@1 SIDEROWF (Andrew)`
A11	`07`	`1`		`@1 WELSH (Mickie)`
A11	`08`	`1`		`@1 POEWE (Werner)`
A11	`09`	`1`		`@1 RASCOL (Oliver)`
A11	`10`	`1`		`@1 SAMPAIO (Cristina)`
A11	`11`	`1`		`@1 STEBBINS (Glenn T.)`
A11	`12`	`1`		`@1 GOETZ (Christopher G.)`
A11	`13`	`1`		`@1 SCHRAG (Anette)`
A14	`01`			`@1 Alzheimer Disease Research Unit, CIEN Foundation-Reina Sofia Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health @2 Madrid @3 ESP @Z 1 aut.`
A14	`02`			`@1 National Center of Epidemiology and CIBERNED, Carlos III Institute of Health @2 Madrid @3 ESP @Z 1 aut. @Z 4 aut.`
A14	`03`			`@1 Department of Rehabilitation, Academic Medical Center @2 Amsterdam @3 NLD @Z 2 aut.`
A14	`04`			`@1 University of Kansas Medical Center, Parkinson's Disease and Movement Disorder Center @2 Kansas City, Kansas @3 USA @Z 3 aut.`
A14	`05`			`@1 Sobell Department of Motor Neuroscience & Movement Disorders, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery @2 Queen Square, London @3 GBR @Z 5 aut.`
A14	`06`			`@1 Department of Neurology, University of Pennsylvania School of Medicine @2 Philadelphia, Pennsylvania @3 USA @Z 6 aut.`
A14	`07`			`@1 Division of Movement Disorders, USC/Keck School of Medicine, University of Southern California @2 Los Angeles, California @3 USA @Z 7 aut.`
A14	`08`			`@1 Department of Neurology, University Hospital @2 Innsbruck @3 AUT @Z 8 aut.`
A14	`09`			`@1 Laboratoire de Pharmacologie Medicale et Clinique @2 Toulouse @3 FRA @Z 9 aut.`
A14	`10`			`@1 Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine @2 Lisbon @3 PRT @Z 10 aut.`
A14	`11`			`@1 Department of Neurological Services, Rush University Medical Center @2 Chicago, Illinois @3 USA @Z 11 aut. @Z 12 aut.`
A14	`12`			`@1 Department of Clinical Neurosciences, Royal Free Hospital, University College London @2 London @3 GBR @Z 13 aut.`
A20				`@1 2371-2380`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000505925010110`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 131 ref.`
A47	`01`	`1`		`@0 12-0026974`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Health-related quality of life is an important patient-reported outcome used in intervention trials and for monitoring the consequences of health status on physical, mental, and social domains. Parkinson's disease is a complex disorder that strongly affects patients' quality of life. Several health-related quality of life tools have been used in Parkinson's disease. A Movement Disorder Society Task Force was commissioned to rate the psychometric quality of available health-related quality of life scales as applied to Parkinson's disease. Following the methodology adopted by previous work of the Movement Disorder Society Task Force, a review of generic and specific health-related quality of life scales applied in studies on Parkinson's disease was completed. Considering the scales from 3 perspectives-use in Parkinson's disease, use by multiple research groups, and clinimetric properties-a final classification as "recommended," "suggested," or "listed" was applied to each reviewed instrument. Four generic scales (EuroQoL, Nottingham Health Profile, 36-Item Short-Form Health Survey, and Sickness Impact Profile) and 5 specific scales (39-Item Parkinson's Disease Questionnaire, Parkinson's Disease Questionnaire Short Form, Parkinson's Disease Quality of Life Questionnaire, Parkinson's Impact Scale, and Scales for Outcomes in Parkinson's Disease-Psychosocial) reached the level of "recommended." The 39-item Parkinson's Disease Questionnaire is the most thoroughly tested and applied questionnaire. Three other generic measures (Quality of Life Questionnaire 15D, Schedule for the Evaluation of Individual Quality of Life-Direct Weighting, and World Health Organization Quality of Life Assessment Short Version) and the specific Parkinson's Disease Quality of Life Scale are "suggested." With a little additional effort in completing the stipulated requirements, they could reach the "recommended" level. At present there is a wide variety of health-related quality of life measures for application in the Parkinson's disease setting, and the task force does not recommend the development of a new scale. Selection of the most appropriate instrument for a particular objective requires consideration of the characteristics of each scale and the goals of the assessment.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Qualité de vie @5 09`
C03	`03`	`X`	`ENG`	`@0 Quality of life @5 09`
C03	`03`	`X`	`SPA`	`@0 Calidad vida @5 09`
C03	`04`	`X`	`FRE`	`@0 Recommandation @5 10`
C03	`04`	`X`	`ENG`	`@0 Recommendation @5 10`
C03	`04`	`X`	`SPA`	`@0 Recomendación @5 10`
C03	`05`	`X`	`FRE`	`@0 Homme @5 11`
C03	`05`	`X`	`ENG`	`@0 Human @5 11`
C03	`05`	`X`	`SPA`	`@0 Hombre @5 11`
C03	`06`	`X`	`FRE`	`@0 Pronostic @5 12`
C03	`06`	`X`	`ENG`	`@0 Prognosis @5 12`
C03	`06`	`X`	`SPA`	`@0 Pronóstico @5 12`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 009`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000345

Links to Exploration step

Pascal:12-0026974

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Health-Related Quality-of-Life Scales in Parkinson's Disease: Critique and Recommendations</title>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Alzheimer Disease Research Unit, CIEN Foundation-Reina Sofia Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Jeukens Visser, Martine" sort="Jeukens Visser, Martine" uniqKey="Jeukens Visser M" first="Martine" last="Jeukens-Visser">Martine Jeukens-Visser</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Rehabilitation, Academic Medical Center</s1>
<s2>Amsterdam</s2>
<s3>NLD</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E." last="Lyons">Kelly E. Lyons</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University of Kansas Medical Center, Parkinson's Disease and Movement Disorder Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Rodriguez Blazquez, C" sort="Rodriguez Blazquez, C" uniqKey="Rodriguez Blazquez C" first="C." last="Rodriguez-Blazquez">C. Rodriguez-Blazquez</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Selai, Caroline" sort="Selai, Caroline" uniqKey="Selai C" first="Caroline" last="Selai">Caroline Selai</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Sobell Department of Motor Neuroscience & Movement Disorders, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery</s1>
<s2>Queen Square, London</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Siderowf, Andrew" sort="Siderowf, Andrew" uniqKey="Siderowf A" first="Andrew" last="Siderowf">Andrew Siderowf</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Welsh, Mickie" sort="Welsh, Mickie" uniqKey="Welsh M" first="Mickie" last="Welsh">Mickie Welsh</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Division of Movement Disorders, USC/Keck School of Medicine, University of Southern California</s1>
<s2>Los Angeles, California</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Neurology, University Hospital</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Laboratoire de Pharmacologie Medicale et Clinique</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Portugal</country>
</affiliation>
</author>
<author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Neurological Services, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Neurological Services, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Department of Clinical Neurosciences, Royal Free Hospital, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0026974</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 12-0026974 INIST</idno>
<idno type="RBID">Pascal:12-0026974</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000345</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002969</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Health-Related Quality-of-Life Scales in Parkinson's Disease: Critique and Recommendations</title>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Alzheimer Disease Research Unit, CIEN Foundation-Reina Sofia Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Jeukens Visser, Martine" sort="Jeukens Visser, Martine" uniqKey="Jeukens Visser M" first="Martine" last="Jeukens-Visser">Martine Jeukens-Visser</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Rehabilitation, Academic Medical Center</s1>
<s2>Amsterdam</s2>
<s3>NLD</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E." last="Lyons">Kelly E. Lyons</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University of Kansas Medical Center, Parkinson's Disease and Movement Disorder Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Rodriguez Blazquez, C" sort="Rodriguez Blazquez, C" uniqKey="Rodriguez Blazquez C" first="C." last="Rodriguez-Blazquez">C. Rodriguez-Blazquez</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Selai, Caroline" sort="Selai, Caroline" uniqKey="Selai C" first="Caroline" last="Selai">Caroline Selai</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Sobell Department of Motor Neuroscience & Movement Disorders, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery</s1>
<s2>Queen Square, London</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Siderowf, Andrew" sort="Siderowf, Andrew" uniqKey="Siderowf A" first="Andrew" last="Siderowf">Andrew Siderowf</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Welsh, Mickie" sort="Welsh, Mickie" uniqKey="Welsh M" first="Mickie" last="Welsh">Mickie Welsh</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Division of Movement Disorders, USC/Keck School of Medicine, University of Southern California</s1>
<s2>Los Angeles, California</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Neurology, University Hospital</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Laboratoire de Pharmacologie Medicale et Clinique</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Portugal</country>
</affiliation>
</author>
<author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Neurological Services, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Neurological Services, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Department of Clinical Neurosciences, Royal Free Hospital, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Human</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Prognosis</term>
<term>Quality of life</term>
<term>Recommendation</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Qualité de vie</term>
<term>Recommandation</term>
<term>Homme</term>
<term>Pronostic</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Recommandation</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Health-related quality of life is an important patient-reported outcome used in intervention trials and for monitoring the consequences of health status on physical, mental, and social domains. Parkinson's disease is a complex disorder that strongly affects patients' quality of life. Several health-related quality of life tools have been used in Parkinson's disease. A Movement Disorder Society Task Force was commissioned to rate the psychometric quality of available health-related quality of life scales as applied to Parkinson's disease. Following the methodology adopted by previous work of the Movement Disorder Society Task Force, a review of generic and specific health-related quality of life scales applied in studies on Parkinson's disease was completed. Considering the scales from 3 perspectives-use in Parkinson's disease, use by multiple research groups, and clinimetric properties-a final classification as "recommended," "suggested," or "listed" was applied to each reviewed instrument. Four generic scales (EuroQoL, Nottingham Health Profile, 36-Item Short-Form Health Survey, and Sickness Impact Profile) and 5 specific scales (39-Item Parkinson's Disease Questionnaire, Parkinson's Disease Questionnaire Short Form, Parkinson's Disease Quality of Life Questionnaire, Parkinson's Impact Scale, and Scales for Outcomes in Parkinson's Disease-Psychosocial) reached the level of "recommended." The 39-item Parkinson's Disease Questionnaire is the most thoroughly tested and applied questionnaire. Three other generic measures (Quality of Life Questionnaire 15D, Schedule for the Evaluation of Individual Quality of Life-Direct Weighting, and World Health Organization Quality of Life Assessment Short Version) and the specific Parkinson's Disease Quality of Life Scale are "suggested." With a little additional effort in completing the stipulated requirements, they could reach the "recommended" level. At present there is a wide variety of health-related quality of life measures for application in the Parkinson's disease setting, and the task force does not recommend the development of a new scale. Selection of the most appropriate instrument for a particular objective requires consideration of the characteristics of each scale and the goals of the assessment.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>26</s2>
</fA05>
<fA06><s2>13</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Health-Related Quality-of-Life Scales in Parkinson's Disease: Critique and Recommendations</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MARTINEZ-MARTIN (Pablo)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>JEUKENS-VISSER (Martine)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>LYONS (Kelly E.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>RODRIGUEZ-BLAZQUEZ (C.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SELAI (Caroline)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>SIDEROWF (Andrew)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>WELSH (Mickie)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>POEWE (Werner)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>RASCOL (Oliver)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>SAMPAIO (Cristina)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>STEBBINS (Glenn T.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>GOETZ (Christopher G.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>SCHRAG (Anette)</s1>
</fA11>
<fA14 i1="01"><s1>Alzheimer Disease Research Unit, CIEN Foundation-Reina Sofia Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Rehabilitation, Academic Medical Center</s1>
<s2>Amsterdam</s2>
<s3>NLD</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>University of Kansas Medical Center, Parkinson's Disease and Movement Disorder Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Sobell Department of Motor Neuroscience & Movement Disorders, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery</s1>
<s2>Queen Square, London</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Neurology, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Division of Movement Disorders, USC/Keck School of Medicine, University of Southern California</s1>
<s2>Los Angeles, California</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Department of Neurology, University Hospital</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Laboratoire de Pharmacologie Medicale et Clinique</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Department of Neurological Services, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Department of Clinical Neurosciences, Royal Free Hospital, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA20><s1>2371-2380</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000505925010110</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>131 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0026974</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Health-related quality of life is an important patient-reported outcome used in intervention trials and for monitoring the consequences of health status on physical, mental, and social domains. Parkinson's disease is a complex disorder that strongly affects patients' quality of life. Several health-related quality of life tools have been used in Parkinson's disease. A Movement Disorder Society Task Force was commissioned to rate the psychometric quality of available health-related quality of life scales as applied to Parkinson's disease. Following the methodology adopted by previous work of the Movement Disorder Society Task Force, a review of generic and specific health-related quality of life scales applied in studies on Parkinson's disease was completed. Considering the scales from 3 perspectives-use in Parkinson's disease, use by multiple research groups, and clinimetric properties-a final classification as "recommended," "suggested," or "listed" was applied to each reviewed instrument. Four generic scales (EuroQoL, Nottingham Health Profile, 36-Item Short-Form Health Survey, and Sickness Impact Profile) and 5 specific scales (39-Item Parkinson's Disease Questionnaire, Parkinson's Disease Questionnaire Short Form, Parkinson's Disease Quality of Life Questionnaire, Parkinson's Impact Scale, and Scales for Outcomes in Parkinson's Disease-Psychosocial) reached the level of "recommended." The 39-item Parkinson's Disease Questionnaire is the most thoroughly tested and applied questionnaire. Three other generic measures (Quality of Life Questionnaire 15D, Schedule for the Evaluation of Individual Quality of Life-Direct Weighting, and World Health Organization Quality of Life Assessment Short Version) and the specific Parkinson's Disease Quality of Life Scale are "suggested." With a little additional effort in completing the stipulated requirements, they could reach the "recommended" level. At present there is a wide variety of health-related quality of life measures for application in the Parkinson's disease setting, and the task force does not recommend the development of a new scale. Selection of the most appropriate instrument for a particular objective requires consideration of the characteristics of each scale and the goals of the assessment.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Qualité de vie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Quality of life</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Calidad vida</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Recommandation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Recommendation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Recomendación</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Homme</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Human</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hombre</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>009</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002969 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002969 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:12-0026974
   |texte=   Health-Related Quality-of-Life Scales in Parkinson's Disease: Critique and Recommendations
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Health-Related Quality-of-Life Scales in Parkinson's Disease: Critique and Recommendations

Health-Related Quality-of-Life Scales in Parkinson's Disease: Critique and Recommendations

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri